Pyelonephritis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pyelonephritis – Drugs In Development, 2024 report and make more profitable business decisions.
Pyelonephritis is a specific type of urinary tract infection (UTI) that generally begins in the urethra or bladder and travels up into the kidneys. Signs and symptoms include fever, abdominal pain, frequent urination, nausea and vomiting, confusion, and back or flank pain. Predisposing factors include weakened immune system, obstruction in the urinary tract, and damage to nerves around the bladder. Treatment includes antibiotics.
The Pyelonephritis drugs in development market research report provide comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pyelonephritis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pyelonephritis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 22 molecules, with 22 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pyelonephritis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pyelonephritis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pyelonephritis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Advanz Pharma Corp LtdAllecra Therapeutics GmbH
Cipla USA Inc
Entasis Therapeutics Holdings Inc
Everest Medicines Ltd
Iterum Therapeutics Plc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Sinoyoung Bio-Pharmaceutical Co Ltd
Meiji Seika Pharma Co Ltd
Melinta Therapeutics LLC
Merck & Co Inc
MerLion Pharmaceuticals Pte Ltd
Nabriva Therapeutics Plc
NRX Pharmaceuticals Inc
Paratek Pharmaceuticals Inc
Pfizer Inc
Qilu Pharmaceutical Co Ltd
Qpex Biopharma Inc
SciClone Pharmaceuticals Holdings Ltd
Shanghai New Asia Pharmaceutical Co Ltd
Spero Therapeutics Inc
VenatoRx Pharmaceuticals Inc
Wockhardt Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pyelonephritis reports